Catalyst Biosciences Future Growth
Future criteria checks 0/6
Catalyst Biosciences is forecast to grow earnings at 75.6% per annum. EPS is expected to grow by 61.4% per annum.
Key information
75.6%
Earnings growth rate
61.4%
EPS growth rate
Biotechs earnings growth | 20.6% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 15 Aug 2023 |
Recent future growth updates
Recent updates
Catalyst Biosciences declares special one-time dividend of $1.43
Aug 25Catalyst Biosciences: Shareholders Should Reap Benefits From Owning The Stock
Aug 15Catalyst Biosciences plans to distribute $65M cash to stockholders
Jun 29Companies Like Catalyst Biosciences (NASDAQ:CBIO) Could Be Quite Risky
Jan 11Circling Back On Catalyst Biosciences
Dec 08Shareholders May Not Be So Generous With Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Compensation And Here's Why
Jun 03Catalyst Biosciences (NASDAQ:CBIO) Will Have To Spend Its Cash Wisely
May 18Catalyst Biosciences EPS misses by $0.12, beats on revenue
May 06Would Shareholders Who Purchased Catalyst Biosciences' (NASDAQ:CBIO) Stock Five Years Be Happy With The Share price Today?
Mar 09We're Hopeful That Catalyst Biosciences (NASDAQ:CBIO) Will Use Its Cash Wisely
Feb 01Catalyst Biosciences announces closing of $50M capital raise
Jan 29Do Institutions Own Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares?
Dec 28Catalyst Biosciences' MarzAA fast track'd for episodic bleeding in hemophilia patients
Dec 02What We Learned About Catalyst Biosciences' (NASDAQ:CBIO) CEO Pay
Dec 02Catalyst Biosciences (CBIO) Presents At Stifel 2020 Virtual Healthcare Conference - Slideshow
Nov 18Catalyst Biosciences: After 2 Fundraisings, A Lengthy Wait For Pivotal Trial Data Is Next
Nov 14Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | N/A | -1 | 0 | N/A | 1 |
12/31/2024 | N/A | -1 | 0 | N/A | 1 |
12/31/2023 | N/A | -6 | N/A | N/A | 1 |
9/30/2023 | N/A | -44 | -13 | -13 | N/A |
6/30/2023 | N/A | -48 | -17 | -17 | N/A |
3/31/2023 | N/A | 7 | -27 | -27 | N/A |
12/31/2022 | 1 | -8 | -33 | -33 | N/A |
9/30/2022 | 3 | 12 | -49 | -49 | N/A |
6/30/2022 | 6 | -8 | -64 | -64 | N/A |
3/31/2022 | 7 | -80 | -72 | -71 | N/A |
12/31/2021 | 7 | -88 | -85 | -84 | N/A |
9/30/2021 | 7 | -87 | -89 | -88 | N/A |
6/30/2021 | 6 | -77 | -80 | -80 | N/A |
3/31/2021 | 6 | -75 | -75 | -75 | N/A |
12/31/2020 | 21 | -56 | -55 | -55 | N/A |
9/30/2020 | 19 | -51 | -41 | -41 | N/A |
6/30/2020 | 18 | -48 | -37 | -37 | N/A |
3/31/2020 | 16 | -44 | -34 | -33 | N/A |
12/31/2019 | N/A | -55 | -44 | -44 | N/A |
9/30/2019 | N/A | -52 | -45 | -45 | N/A |
6/30/2019 | N/A | -47 | -43 | -42 | N/A |
3/31/2019 | N/A | -40 | -39 | -38 | N/A |
12/31/2018 | 0 | -30 | -29 | -29 | N/A |
9/30/2018 | 0 | -25 | -26 | -26 | N/A |
6/30/2018 | 1 | -23 | -24 | -24 | N/A |
3/31/2018 | 1 | -26 | -21 | -21 | N/A |
12/31/2017 | 1 | -26 | -20 | -20 | N/A |
9/30/2017 | 1 | -24 | -19 | -19 | N/A |
6/30/2017 | 1 | -22 | N/A | -19 | N/A |
3/31/2017 | 1 | -17 | N/A | -18 | N/A |
12/31/2016 | 0 | -17 | N/A | -18 | N/A |
9/30/2016 | 0 | -18 | N/A | -19 | N/A |
6/30/2016 | 0 | -19 | N/A | -23 | N/A |
3/31/2016 | 1 | -15 | N/A | -21 | N/A |
12/31/2015 | 2 | -15 | N/A | -19 | N/A |
9/30/2015 | 2 | -11 | N/A | -16 | N/A |
6/30/2015 | 3 | -7 | N/A | -7 | N/A |
3/31/2015 | 2 | -8 | N/A | -8 | N/A |
12/31/2014 | 2 | -7 | N/A | -6 | N/A |
12/31/2013 | 1 | -10 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CBIO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CBIO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CBIO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if CBIO's revenue is forecast to grow faster than the US market.
High Growth Revenue: CBIO is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CBIO's Return on Equity is forecast to be high in 3 years time